×

RNS Number : 5971X

Tracsis PLC

19 February 2025

 

19 February 2025

 

Tracsis plc

("Tracsis" or "the Group")

 

Contract signed for pay-as-you-go Tap Converter system

 

Tracsis (LSE: TRCS), a leading transport technology provider, is pleased to announce that, further to the announcement of Preferred Bidder status on 26 November 2024,  it has signed a multi-year contract withRail Settlement Plan, a division of Rail Delivery Group (RDG), to implement the core Tap Converter system that will powerpay-as-you-go (PAYG) travel in urban areas across National Rail, processing all related transactions and fare calculations.

 

Highlights

 

·     Major contract win, through a competitive bid process, to provide the central smart ticketing technology platform enabling PAYG travel in urban areas across National Rail.

·     The nationwide rollout of PAYG is central to the UK Government's stated vision for modernising rail travel with ticketing simplification and innovation high on its agenda.

·     Six Train Operating Companies (TOCs) on theNational Rail network currently use Tracsis' smart ticketing technology. This contract provides a long-term revenue opportunity as TOC and consumer adoption grows.

·     All Tracsis development activities are fully funded. Once deployed, the contract delivers a guaranteed minimum annual operating fee with additional transaction revenues based on the volume of PAYG transactions processed.

·     Development starts immediately with deployment and transactional revenue generation expected to begin in 2026.

 

Background

 

The Tap Converter system will be a centralised smart ticketing technology platform that processes 'tap' data from various sources such as smartcards, contactless bankcards and mobile apps/barcodes when passengers tap in and out at stations. It will also integrate with multiple modes of transport, supporting the delivery of London style PAYG ticketing for rail, bus and tram travel.

 

Tracsis will utilise its existing technology to construct journeys from these taps calculating the best fare while automatically applying entitlements, concessions, discounts and fare caps. Once calculated, the system provides this fare information to the TOC to charge the passenger and submits settlement records to the rail industry's settlement engine.

 

Tracsis is currently the only provider of an accredited PAYG ticketing platform on the National Rail network outside London, and this contract significantly extends the potential reachof Tracsis' technology. With the government and industry-wide push towards smarter, more flexible digital ticketing, PAYG adoption is expected to expand across the network, though the pace will vary by operator and region.

 

Timeline, Opportunity and Revenue Model

 

Tracsis has begun a period of funded development with deployment expected to begin in 2026. The six TOCs currently offering a PAYG solution using Tracsis' technology will continue to do so during this period.

 

Once the Tap Converter system is operational, Tracsis revenues will be based on the volume of transactions processed and this willbe driven by future customer adoption rates and system usage.

 

A total of 1.7 billion rail passenger journeys were recorded across Great Britain in the 12 months to September 20241.Tracsis estimates that PAYG transaction volumes using the Tap Converter system could in the medium term equate to 10-15% of total annual passenger journeys with commuters expected to drive the highest adoption rates.    

 

In 2024, Tracsis processed 2.25 million PAYG journeys. With the recent go-live of new PAYG deployments in Wales (contactless EMV) and Scotland (Tap&Pay) we expect to see accelerated growth in passenger journeys over the coming months ahead of the deployment of the Tap Converter system.

 

Transaction revenues from the Tap Converter system will start to accrue following deployment which is forecast to start in 2026. There is no change to the Board's expectation for the year ending 31 July 2025 following this contract win and Tracsis will issue its trading update on H1 performance on 26 February 2025.

 

Chris Barnes, Chief Executive Officer of Tracsis, commented:

 

"Weare delighted to be working with the Rail Delivery Group and Great British Railways Transition Team (GBRTT) to deliver this important pay-as-you-go ticketing solution on a nationwide basis. The contract represents a major milestone in our smart ticketing technology journey, with the potential to grow into a valuable, long-term partnership over time.

 

Digital transformation remains integral to the rail industry's future. The Government has made a commitment to expand pay-as-you-go ticketing across urban areas on the National Rail network and the Tap Converter system will position Tracsis as an important technology provider at the heart of this transformation."

Stewart Fox-Mills, Fares, Ticketing and Retail Programme Director at GBRTT and RDG, commented:

"We are working with industry partners to simplify the railway fares and ticketing system, making travel more convenient and flexible for all passengers. We are committed to developing a simpler fare system that enhances the overall customer experience and supports the long-term growth of rail travel.

The delivery of pay-as-you-go ticketing in urban areas is a high priority and we look forward to working with Tracsis on delivering the Tap Converter system that will provide the technical foundation for pay-as-you-go ticketing in urban areas."

 

1Source: Office of Rail and Road passenger rail usage data (published 19 December 2024)Passenger rail usage | ORR Data Portal

 

Enquiries:

Tracsis plc Chris Barnes, CEO Andy Kelly, CFO	+44 (0)845 125 9162
Berenberg (Nominated Adviser, Corporate Broker & Financial Adviser) Mark Whitmore / Richard Andrews / Mollie D'Arcy Rice James Thompson (QE)	+44 (0)20 3207 7800
Alma Strategic Communications David Ison / Rebecca Sanders-Hewett / Joe Pederzolli	+44 (0)20 3405 0205 tracsis@almastrategic.com

 

Notes to editors: 

 

·     Tracsis plc is a technology company and a leading provider of software and hardware products, data capture and data analytics/GIS services for the rail, traffic data and wider transport industries.

 

·     Tracsis's products and services are widely used to increase efficiency, reduce cost and risk, improve operational and asset performance, improve safety management and decision making capabilities and improve the overall end-user experience for clients and customers. 

 

·     The Group is split into two principal operating areas built around detailed industry knowledge and expertise:

 

–      Rail Technology & Services: A software, technology and product led business. It develops and supplies software that solves complex resource, asset optimisation and control problems for Train Operators, and smart ticketing, delay repay and other retail software to improve the customer experience for rail users. It also develops remote condition monitoring hardware, data acquisition software, and safety and risk management software for rail infrastructure providers.

–  Data, Analytics, Consultancy & Events: A largely services led business that focuses on data capture, data analytics, GIS, earth observation, data insights, consultancy and event traffic management within a range of transport and pedestrian rich environments. The business provides technology and bespoke products and data that underpin large scale intelligent transport systems, smart city planning and positive environmental decision making.

 

·     Tracsis has a blue-chip client base which includes all major UK transport owning groups, Network Rail, Passenger and Freight Train Operating Companies, the Department for Transport, TfL, multiple local authorities, major outdoor music and sporting event organisers, and a wide variety of large engineering and infrastructure companies. In North America our clients include Class 1 rail freight companies, transit operators, shortline railroads and several large rail served ports and industrials.

 

·     The business drives growth both organically and through acquisition and has made seventeen acquisitions since 2008.

 

For more information on Tracsis please visit http://www.tracsis.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

CNTUWURRVVUUAUR

Close

×

RNS Number : 5703W

Newbury Racecourse PLC

11 February 2025

 

 

RNS Reach – non-regulatory announcement

 

11 February 2025

NEWBURY RACECOURSE PLC

(the "Company")

 

2025 Party in The Paddock

 

The Company today announces the final act to complete its 2025 Party in the Paddock line-up. In the past, the Company has hosted established acts such as Tom Jones, Meat Loaf, Olly Murs and Simply Red who have performed after racing at two key summer Saturday fixtures.

 

For 2025 the Company will be expanding these events and hosting a total of four events, the first of which is a double-headline combination of Sophie Ellis-Bextor and Ella Henderson on Saturday 19th July. Following this, Bjorn Again will perform on Friday 15th August and Clean Bandit on Saturday 16th August. James Bay will complete this year's line-up with a performance after racing on Saturday 20th September.     

 

Tickets are available to purchase fromwww.newburyracecourse.co.ukwith discounts offered for early and multi-day commitment.

 

Shaun Hinds, Chief Executive of Newbury Racecourse, commented: "We are delighted to announce an expanded Party in the Paddock line-up for 2025. By hosting this strong line up of established and popular artists we are hopeful that we have catered for a broad variety of music tastes and look forward to a fantastic summer of music and racing at Newbury".

 

 

 

For further information please contact:

 

Newbury Racecourse plc                                                                             Tel: 01635 40015

Shaun Hinds, Chief Executive

Mark Leigh, Finance Director

 

Allenby Capital Limited (AQSE Corporate adviser)                                  Tel: 0203 328 5656

Nick Naylor / Liz Kirchner (Corporate Finance)                   

 

Hudson Sandler                                                                                              Tel: 0207 796 4133

Charlie Jack

 

About Reach announcements

This is a RNS Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain.  Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRASFAFISEISEFE

Close

×

RNS Number : 5923W

Smarttech247 Group PLC

11 February 2025

 

Reach Announcement

11 February 2025

Smarttech247 Group PLC

 

("Smarttech247", the "Group" or the "Company")

 

Smarttech247 Secures Three-Year Contract Worth USD 925,000

 

Smarttech247 (AIM: S247), a multi-award-winning provider of AI-enhanced cybersecurity services providing automated managed detection and response for a portfolio of international clients, is pleased to announce it has signed a new additional contract with an existing automotive client worth USD 925,000 over three years.

 

This new additional contract will see an Endpoint Detection & Response (EDR) solution integrated into the existing Managed Detection and Response (MDR) service already supplied to Smarttech247's automotive client. This new EDR solution is designed to detect, investigate and respond to threats on endpoint devices such as computers, laptops, and servers, enhancing the client's existing cybersecurity resilience.

 

This new contract also reflects the execution of the Company's strategy to expand its annual recurring revenue by focusing on long-term, multi-year contracts and increasing the total contract value of existing agreements.

 

Raluca Saceanu, CEO of Smarttech247, commented:

 

"We are thrilled to be expanding our provision of services with another existing client, reinforcing our strong, ongoing relationship and highlighting the continued trust our clients have in our MDR expertise to protect their critical infrastructure.

 

"As organisations worldwide increasingly prioritise advanced threat detection and response, this latest contract showcases our ability to deliver security solutions at scale as our momentum continues to build."

 

-Ends –

 

*Smarttech247 is a recognised vendor in 2024 Gartner® Market Guide for Managed Detection and Response. 

 

For further information please contact:

 

Smarttech247 Group PLC	Tel: +353 21 206 6033
Ronan Murphy, Executive Chairman   Raluca Saceanu, Chief Executive Officer   Nicholas Lee, Finance Director
SPARK Advisory Partners Limited – Nominated Adviser	Tel: + 44 (0) 20 3368 3550
Mark Brady / Angus Campbell
Cavendish Capital Markets Limited – Corporate Broker	Tel: +44 (0) 20 7220 0500
Marc Milmo / Hamish Waller Tim Redfern / Sunila de Silva – Broking
Yellow Jersey PR	Tel: +44 (0) 20 3004 9512
Charles Goodwin / Annabelle Wills / Bessie Elliot

 

About Reach announcements

 

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only/non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

 

About Smarttech247

 

Smarttech247 is a multi-award winning automated MDR (Managed Detection & Response) company. Its platform is trusted by international organisations and provides threat intelligence with managed detection and response to provide actionable insights, 24/7 threat detection, investigation and response.

 

The Group's services are geared towards proactive prevention, and it achieves this by utilising the latest technologies, along with an experienced incident response team.

 

Smarttech247's offices are located in Ireland, United Kingdom, Romania, Poland and the USA. The Company was admitted to trading on the London Stock Exchange on 15 December 2022.

 

For further information please visitwww.smarttech247.com

 

*Gartner disclaimers

 

Market Guide for Managed Detection and Response, 24 June 2024, Pete Shoard, Andrew Davies, Mitchell Schneider, Angel Berrios, Craig Lawson.

 

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

 

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the

U.S. and internationally and is used herein with permission. All rights reserved.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAGPUAGPUPAGBU

Close

×

RNS Number : 9223V

Oxford BioDynamics PLC

05 February 2025

 

 

Oxford BioDynamics plc

("Oxford BioDynamics" or the "Company")

Oxford BioDynamics' EpiSwitch® CRC Blood Test Accurately
Detects both Cancer and Polyps

 

·   Results of multi-institutional clinical study published in peer reviewed journal 'Cancers' confirms efficacy of Oxford BioDynamics' EpiSwitch® blood-based Colorectal No-Stool Test (NST)

·   High accuracy of detection reported at 81% for early cancer stages and 82% for non-cancerous polyps

·   Discussions are underway with potential partners to bring this potentially evolutionary test to clinical practice

 

Oxford, UK – 5 February 2025– Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces the publication of compelling results involving OBD's technology in a multi-centre study using blood to detect colorectal cancer (CRC), including early stage, and non-cancerous polyps with high accuracy1. 

 

The peer-reviewed work, published in the high-impact journal 'Cancers', was a collaboration between OBD, Norwich Medical School (University of East Anglia), University Hospitals NHS Trust, Hospital Sultana Bahiyah, Island Hospital Penang, Hospital Pulau Pinang, Hospital Sultanah Aminah, and Mount Miriam Cancer Hospital (Malaysia) under the direction of leading UK and Malaysian colorectal cancer experts.

 

Usingbloodsamples collected from 325 patients, the whole genome DNA screening for 3D EpiSwitch biomarkers in blood has identified and validated two eight-marker signatures (EpiSwitch® NST) that allow diagnosis of CRC andprecancerous polyps, respectively. Independent validation cohort testing demonstrated an exceptionally highaccuracy of detection – 81% for early cancer stages and 82% for non-cancerous polyps.Linking the top diagnostic biomarkers to nearby genes, OBD used the EpiSwitch KnowledgeBase platform to map pathways that help understand the processes contributing to the pathology of polyp and CRC progression.

 

Principle clinical lead Prof. Dmitry Pchejetski, Ph.D., Professorial Research Fellow and Head of the Tumour Microenvironment and Chemotherapy group at Norwich Medical School,said:

"I am excited by these findings. This test has the potential ability to detect early cancers and precancerous polyps with greater accuracy."

 

Dr Alexandre Akoulitchev, OBD's Chief Scientific Officeradded:

"Reliable and non-invasive detection of early stages of colorectal cancer, as well as the polyps, has been the focus of strenuous efforts by a number of big biomarker companies deploying common biomarker modalities. To date the results in terms of sensitivity of detection for polyps and positive predictive value for cancer have been disappointing. Our own approach and these reported results demonstrate the consistent accuracy of EpiSwitch technology for the most challenging patient stratifications and will allow us to progress our ongoing commercial discussions with third parties."

 

The peer-reviewed manuscript, titled "A New Blood-Based Epigenetic Diagnostic Biomarker Test (EpiSwitch® NST) with High Sensitivity and Positive Predictive Value for Colorectal Cancer and Precancerous Polyps" is available online in Cancers1 (www.mdpi.com/2072-6694/17/3/521).

 

Colorectal cancer

Globally, CRC is the third most common cancer type, accounting for 10% of all cancer cases. There were 1.9 million new cases and 930,000 deaths from the disease in 2020. More than 80% of CRC arises from adenomatous polyps and outgrowths. Around 75-95% of CRC cases occur in people with little or no genetic risk. Screening modalities such as colonoscopy, faecal immunochemical tests (FIT), FIT-DNA and cell-free DNA from CRC tumours in blood are current primary screening tests for early detection and prevention. Unfortunately, the non-invasive methods lack sensitivity to polyps and early CRC.

 

OBD's EpiSwitch pipeline development has delivered a blood-based Colorectal No-Stool Test (NST) which shows significant potential as an accurate and rapid cancer screening diagnostic for early stages of cancer (sensitivity 84% and specificity 79%) and non-cancerous polyps (sensitivity 79% and specificity 83%). This accurate, rapid, minimally invasive, and cost-effective NST test was built using OBD's EpiSwitch® 3D genomics platform and methodology. For each patient, NST captures a personal, systemic fingerprint of specific regulatory network changes associated with early stages of colorectal cancer and/or non-cancerous polyps.

 

References
1"A New Blood-Based Epigenetic Diagnostic Biomarker Test (EpiSwitch® NST) with High Sensitivity and Positive Predictive Value for Colorectal Cancer and Precancerous Polyps"Ewan Hunter 1, Heba Alshaker 2, Cicely Weston 1, Mutaz Issa 1, Shekinah Bautista 1, Abel Gebregzabhar 1, Anya Virdi 1, Ann Dring 1, Ryan Powell 1, Jayne Green 1, Roshan Lal 3, Vamsi Velchuru 3, Kamal Aryal 3, Muhammad Radzi Bin Abu Hassan 4, Goh Tiong Meng 5, Janisha Suriakant Patel 6, Shameera Pharveen Mohamed Gani 6, Chun Ren Lim 6, Thomas Guiel 7, Alexandre Akoulitchev  and Dmitri PchejetskiCancers2025, 17, 521. (https://www.mdpi.com/2072-6694/17/3/521)

 

-Ends-

 

For more information:

 

Oxford BioDynamics PLC Iain Ross, Executive Chairman Paul Stockdale, CFO	+44 (0)1865 518910
Shore Capital – Nominated Adviser and Joint Broker Advisory: Stephane Auton / Lucy Bowden Broking: Fiona Conroy	+44 (0)20 7408 4090
OAK Securities –JointBroker Jerry Keen / Henry Clarke /Damion Carruel	+44 (0)203 973 3678
WG Partners – Joint Broker David Wilson / Claes Spång /Satheesh Nadarajah / Erland Sternby	+44 (0)20 3705 9330
Vigo Consulting  Media / Analyst enquiries for OBD Rozi Morris	+44 (0)20 7390 0230 obd@vigoconsulting.com

 

 

Notes for Editors

 

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.

 

Currently OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.

 

The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.

 

OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.

 

The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.

 

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com,  X (@OxBioDynamics) or LinkedIn.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRASSIEFLEISEDE

Close

×

RNS Number : 8387T

Powerhouse Energy Group PLC

20 January 2025

 

 

20 January 2025

 

Powerhouse Energy Group Plc

("Powerhouse", "PHE" or the "Company")

 

Proposed collaboration agreement with Avioxx for the production of SAF

Powerhouse (AIM:PHE), a company pioneering integrated technology that converts non-recyclable waste into low carbon energy together with a revenue generating engineering consulting division (Engsolve), is pleased to announce that the Company has agreed to collaborate  with Avioxx Ltd (www.avioxx.com)to integrate PHE's technology for its pilot scale facility to produce 200 tonnes per annum of Sustainable Aviation Fuel ("SAF"). Avioxx, based in London and Cheshire, has developed a patented process to produce SAF from non-recyclable wastes.

Under the proposed collaboration, PHE will work with Avioxx on its pilot scale facility, Project Eden, which is expected to produce 200 tonnes per annum of SAF.  The companies are currently investigating the potential of PHE providing two 2.5 tonne per day gasification trains to supply the raw syngas to feed the facility.  The 2.5 tonne per day units are based upon the Powerhouse's Feedstock Testing Unit at the Company's Technical Centre in Bridgend.  These units will be sold to Avioxx, with a potential service agreement going forward between PHE and Avioxx.  The integration of the two companies' patented technologies is illustrated in the 3D rendering shown in the figure below.

 

 

PHE sees this as an important route to a lower carbon future and the Company's patented DMG (Distributed Modular Generation) is ideal for the smaller scale facilities and will allow its viability as a supplier of Syngas to large scale SAF facilities to be assessed.

Project Eden is still in the development phase and more information about the project and Avioxx can be found athttps://www.avioxx.co.uk/project-eden-200-TPA-modular-plant.html

Details of the Powerhouse Energy Group DMG can be found atwww.phegroup.com

 

Paul Emmitt, Chief Executive Officer of Powerhouse, commented:

"We are delighted to be collaborating with Avioxx. This is a highly significant development for the Company as it further shows the potential of our technology and its adaptability to be able to service a wide number of industries.  SAF has huge potential for us and is a sector that undoubtedly can benefit from using our technology to provide cleaner fuels for the aviation industry. 

"We look forward to working with the Avioxx team in progressing Project Eden and providing further updates in due course."

 

Chris Hancock, Chief Executive Officer of Avioxx, commented:

"Effectively harnessing the valuable molecules from waste is key to achieving a genuine circular economy and delivering economical, sustainable fuel for the aviation sector. We hope the Powerhouse technology will be the first, and most important stage of the process to transform waste to highly valuable fuel. Integration of electrochemistry allows us to dramatically improve the production efficiency of the Jet A1 kerosine. It's great to be working with Paul and the team."

 

For more information, contact:      

Powerhouse Energy Group Plc

Paul Emmitt, CEO                                                                  +44 (0) 203 368 6399

Strand Hanson Limited(Nominated & Financial Adviser)

Ritchie Balmer / James Harris / Rob Patrick                         +44 (0) 207 409 3494

SP Angel Corporate Finance LLP(Broker)

Stuart Gledhill / Adam Cowl                                                   +44 (0) 20 3470 0470

Tavistock(Financial PR)

Simon Hudson / Nick Elwes / Saskia Sizen                           +44 (0) 207 920 3150

powerhouse@tavistock.co.uk

 

About Powerhouse Energy Group Plc

Powerhouse has developed a process technology which can utilise waste plastic, end-of-life-tyres, and other waste streams to convert them efficiently and economically into syngas from which valuable products such as chemical precursors, hydrogen, electricity, heat and other industrial products may be derived. PHE's process produces low levels of safe residues and requires a small operating footprint, making it suitable for deployment at enterprise and community level.

PHE also incorporates Engsolve Ltd, which is a revenue generating business offering Engineering Services across all sectors, with speciality services in the development of new technologies and clean energy.

For more information, seewww.phegroup.com

 

About Avioxx

Avioxx is a UK-based clean energy company pioneering next-generation sustainable aviation fuel production. With a patented solid oxide fuel cell technology, Avioxx is committed to making SAF cost-competitive with traditional jet fuel, reducing aviation emissions, and securing Britain's energy independence.

For more information, see www.avioxx.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAQDLFFEFLZBBV

Close

×

Neville Registrars are delighted to welcome Praetura Growth VCT plc as the newest addition to its list of client companies.

Praetura Growth VCT plc have been providing market-leading investments for advisers and investors since 2011. Their team of experts from across the industry are passionate about finding the best oppportunies in EIS, VCT and BR qualifying companies. 

Further information can be found on the Company's website: www.praeturainvestments.co.uk

 

Close

×

RNS Number : 7034M

ValiRx PLC

19 November 2024

 

19 November 2024

 

ValiRx PLC

("ValiRx" or the "Company")

 

Contract Award

 

London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following contract award update from its wholly owned subsidiary Inaphaea BioLabs Limited ("Inaphaea").

Inaphaea is delighted to confirm the execution of a further contract for the provision of cell-based assays to UK biotech company, Amply Discovery Limited ("Amply"). The multiphase contract, potentially worth over £100,000 over a 8 month period, will evaluate various formulations of Amply's developmental siRNA targets in Inaphaea's Triple Negative Breast Cancer (TNBC) Patient Derived Cells (PDCs) as stand-alone agents and in combination with standard of care drugs. The deal includes an upfront payment to Inaphaea of approximately £31,000 with an additional approximately £21,000  payment on completion of the first phase after 4 months and £10,500 on completion of the remaining in-vitro phase after a further 6 weeks. Successful candidates have the option to be evaluated in-vivo using selected PDCs through one of Inaphaea's partners.

Andrew Carnegie, Head of Strategic Commercial Development at Inaphaea, commented"It is exciting to have secured this contract, which aligns our services with one of our strategic partners, and defines a good roadmap for future clients."

Mark Eccleston, CEO of ValiRx commented"This is an important contract for Inaphaea as it validates our partnered approach to offering full-service capabilities to our clients."

Dermot Tierney, COO of Amply commented"We are happy to be working with Inaphaea on this critical phase of Amply's development pathway. It was important for us to find a CRO partner who could manage the whole process with agreed milestones."

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company take responsibility for this announcement.

 

*** ENDS ***

 

For more information, please contact:

 

ValiRx plc   Dr Mark Eccleston, CEO	Tel: +44 (0) 2476 796496 www.valirx.com Mark.Eccleston@valirx.com
V Formation (Public Relations)   Lucy Wharton – Senior PR Executive Sue Carr – Director	+44 (0) 115 787 0206 www.vformation.biz   lucy@vformation.biz sue@vformation.biz
Cairn Financial Advisers LLP (Nominated Adviser)   Liam Murray/ Ludovico Lazzaretti	Tel: +44 (0) 20 7213 0880
Shard Capital Partners LLP (Sole Broker)   Damon Heath	Tel: +44 (0) 20 7186 9000

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. 

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit:www.valirx.com

 

Cautionary statement

Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

CNTXVLLFZFLFFBV

Close

×

RNS Number : 8036M

Kanabo Group PLC

19 November 2024

 

19 November 2024

Kanabo Group Plc

The GP Service Wins Award

Kanabo Group Plc ("Kanabo" or "the Company"), a leader in medical cannabis and telemedicine innovation, is pleased to announce that its subsidiary, The GP Service, has been named the winner of the Lloyds British Business Excellence Award for Tech Business of the Year. This prestigious recognition highlights The GP Service's leadership in healthcare technology, competing with some of the UK's most forward-thinking companies.

 

Strategic Growth and Innovation

Since its acquisition by Kanabo in February 2022, The GP Service has strengthened its position in the healthcare market through its robust technology platform and a network of over 6,000 pharmacies across the UK. This infrastructure facilitates secure and seamless electronic prescription delivery, demonstrating its scalability as a patient-focused solution bridging the gap between technology and accessible healthcare.

To align with its strategy of profitability and operational efficiency, The GP Service has restructured its clinical operations by outsourcing services to trusted third-party providers. This move reduces regulatory complexity while sharpening its focus on technology and scalability. This strategic shift enables The GP Service to concentrate on developing innovative solutions that enhance patient access and clinician support.

AI-Driven Expansion

The GP Service continues to refine its proprietary AI-powered Voice and Chat Bot technology, incorporating patient feedback and further testing to optimize its capabilities. Initial beta tests have shown promise. By automating patient consultations, gathering medical data, and supporting clinicians with prescription recommendations, this solution is poised to reduce administrative burdens, improve patient care, and enhance scalability.

 

Suleman Sacranie, Co-Founder of The GP Service, commented:

"This award is a powerful validation of our mission to make healthcare more accessible, efficient, and patient-focused. Competing against the UK's top technology companies, we're honored to be recognised for our innovation and impact. We look forward to continuing to redefine telemedicine and deliver value to patients and partners."

 

Ian Mattioli, Chairman of Kanabo Group Plc, added:

"The GP Service's recognition as Tech Company of the Year demonstrates its potential to set new benchmarks in healthcare innovation. While Kanabo supports its growth, The GP Service continues to chart its course as a scalable, technology-driven business delivering value to patients and partners."

 

Enquiries:

Kanabo Group plc Avihu Tamir, Chief Executive Officer Ian Mattioli, Non-Executive Chair of the Board
Peterhouse Capital Ltd (Financial Adviser)	+44 (0)20 7469 0930

 

About Kanabo Group Plc

Kanabo Group Plc is a pioneering developer of medical cannabis and telemedicine solutions. Through strategic acquisitions and innovative technologies, the company is shaping the future of global healthcare accessibility and outcomes.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAUKVKRSSUAARA

Close

×

RNS Number : 2653M

Marula Mining PLC

14 November 2024

 

 

 

 

 

Marula Mining PLC

("Marula'' or the "Company")

 

14 November 2024

 

Aquis Showcase 2024 Winner

 

Marula Mining (AQSE: MARUA2X: MARU) an African focused mining and development company, is pleased to announce that it was selected as the ultimate winner of the Aquis Showcase 2024 event held on 12 November 2024.

 

The Company hosted a presentation amongst two additional other companies and was voted by the audience as the winner of its own group. In total, 13 companies participated in the Aquis Showcase presentations. Marula was then selected as the final winner at the grand final following deliberation between the institutional investor panel.

 

The Directors of Marula are responsible for the contents of this announcement.

 

About Marula Mining

Marula Mining (AQSE: MARU A2X: MARU) is an African focused battery metals investment and exploration company and has interests in several high value mining operations and mine development projects in Africa: the Blesberg Lithium and Tantalum Mine, Northern Cape Lithium and Tungsten Project, Korridor Lithium Project  and Kruisrivier Cobalt Mine, all in South Africa; the Larisoro Manganese Mine and Kilifi Manganese Processing Operation both in Kenya; the Kinusi Copper Mine, the Nyorinyori Graphite Project, the NyoriGreen Graphite Project and the Bagamoyo Graphite Project all in Tanzania and the Nkombwa Hill Project in Zambia. As we advance operations at these battery metals focused projects, Marula will continue to build and expand its interests in other high-quality projects in Africa.

Marula's strategy is to identify and invest in advanced and high-value mining projects throughout East, Central and Southern Africa that the Directors believe would deliver returns for its shareholders. The Board and management team aims to establish Marula as a socially and environmentally responsible, sustainable, and profitable producer of critical metals and commodities that are of increasingly strategic importance to modern technologies and the global economy. Marula's shares are traded on AQUIS Stock Exchange (AQSE) in London and A2X Markets in South Africa. Marula is exploring opportunities to admit its shares to trading on Kenya's Nairobi Securities Exchange and South Africa's Johannesburg Stock Exchange.

 

For enquiries contact:

 

Marula Mining PLC Jason Brewer, Chief Executive Officer   Faith Kinyanjui Mumbi Investor Relations	Email : jason@marulamining.com   Email : info@marulamining.com
Broker Peterhouse Capital Limited, Charles Goodfellow / Duncan Vasey	+44 (0)20 7469 0930
Financial PR and IR BlytheRay Tim Blythe / Megan Ray / Said Izagaren	+44 (0)20 7138 3204
A2X Advisor AcaciaCap Advisors Proprietary Limited Michelle Krastanov	+27 (11) 480 8500

 

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAFFLSULELSESF

Close

×

RNS Number : 2697L

Shearwater Group PLC

07 November 2024

 

7 November 2024

Shearwater Group PLC

 

("Shearwater", or the "Group")

 

Contract Win, G-Cloud Supplier Status Approved and Notice of Results

 

Shearwater Group plc, the cybersecurity, advisory, and managed security services group, is pleased to announce that its subsidiary, Brookcourt Solutions ("Brookcourt"), has secured a significant three-year contract with a major British media and telecommunications company. It also announces that it has achieved 'approved supplier' status with the Crown Commercial Service ("CCS"), G-Cloud 14 framework, which all public sector organisations can use to buy cloud-based computing services such as hosting, software and cloud support.

Contract win withBritish Media and Telecoms giant

Brookcourt has secured a significant three-year contract, valued at c.£3.7m. The contract will be recognised in the current financial year and contributes towards the FY25 revenue target.  It includes a comprehensive renewal of endpoint security platforms, along with advanced Data Loss Prevention (DLP) and Identity Protection solutions, reinforcing the client's security posture for years to come.

Approved supplier status with the Crown Commercial Service

Brookcourt's recognition as 'approved supplier' with the CCS is strategically significant and aligns with Shearwater's recent focus on expansion into Government departments.

Brookcourt is now able to provide a broad array of cybersecurity servicesdesigned to address the unique cybersecurity challenges faced by public sector organisations. The portfolio includes solutions enhanced by generative artificial intelligence (AI), providing buyers with powerful tools to streamline operations through automation and technological innovation.

The G-Cloud 14 framework will operate for an initial period of 18 months, extendable up to two years – doubling the term of the previous framework. Contracts awarded through this framework may run for up to four years, allowing Brookcourt to deliver sustained, high-quality cybersecurity solutions to public sector clients.

Notice of Results

The Group will provide a full update on trading together with its interim results, which will be announced on 26 November 2024.

Phil Higgins, CEO of Shearwater, commented:

"Securing approved supplier status on the Crown Commercial Service's G-Cloud 14 framework underscores our commitment to delivering innovative, high-impact cybersecurity solutions for the public sector, and demonstrates the value of the Shearwater offering.

This achievement, alongside our significant new contract with a leading British media and telecommunications company, reaffirms our dedication to empowering clients with next-generation security tools, including advanced AI-driven solutions.

We look to the future with confidence, bolstered by increased levels of customer engagement, deepened expansion into central government and a growing pipeline of opportunities."

Enquiries:

 

Shearwater Group plc David Williams, Chairman Phil Higgins, CEO Jonathan Hall, CFO	www.shearwatergroup.com c/o Alma
Cavendish Capital Markets Limited– NOMAD and Broker Adrian Hadden / Ben Jeynes / Fergus Sullivan – Corporate Finance Henry Nicol / Dale Bellis / Michael Johnson – Sales	+44 (0) 20 7220 0500
Alma Strategic Communications Justine James / Joe Pederzolli / Emma Thompson	shearwater@almastrategic.com +44 (0) 20 3405 0205

 

About Shearwater Group plc

 

Shearwater Group plc is an award-winning group providing cyber security, managed security and professional advisory solutions to create a safer online environment for organisations and their end users.

 

The Group's differentiated full service offering spans identity and access management and data security, cybersecurity solutions and managed security services, and security governance, risk and compliance. Its growth strategy is focused on building a scalable group that caters to the entire spectrum of cyber security and managed security needs, through a focused buy and build approach.

 

The Group is headquartered in the UK, serving customers globally across a broad spectrum of industries.

 

Shearwater shares are listed on the London Stock Exchange's AIM under the ticker "SWG".  For more information, please visit www.shearwatergroup.com.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

CNTDBBDBCDGDGSL

Close